New research by School of Nursing professor Sheila Ridner finds that a special scan measuring lymphatic fluid volume is significantly better than a tape measure at predicting which women undergoing treatment for breast cancer are at risk of developing a common complication resulting from damaged lymph nodes.
A new study has shown that more than half of physicians -- primary care doctors and specialists -- may be unaware that dense breasts are associated with an increased risk of breast cancer, and nearly half reported not being aware of laws requiring physicians to inform women about mammography-related breast density risks and supplemental screening options.
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of experiencing side-effects from their radiation therapy, while cure rates are almost identical between the two groups.
The five states and District of Columbia that first adopted Medicaid expansion saw larger increases in cancer screening than those states that did not.
A new paper in JNCI Cancer Spectrum, published by Oxford University Press, is the first study to find that diets high in soy foods are associated with a decreased risk of osteoporotic bone fractures in pre-menopausal breast cancer survivors.
A University of California, Riverside, research team has come up with a new approach to targeting cancer cells that circumvents a challenge faced by currently available cancer drugs.
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published today in the journal Science Translational Medicine, suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific pathway -- or process -- to create DNA repair cells.
Michigan State University researchers are analyzing large volumes of data, often referred to as big data, to determine better research models to fight the spread of breast cancer and test potential drugs. Current models used in the lab frequently involve culturing cells on flat dishes, or cell lines, to model tumor growth in patients.
A team of Brazilian researchers has developed a strategy that slows the growth of triple negative breast cancer cells by cutting them off from two major food sources.